Document is current
Any future updates will be listed below
-
Authors
Kurtansky, Nicholas R.
Gillis, Maura C.
Codella, Noel C. F.
D’Alessandro, Brian M.
Ge, Zongyuan
Guitera, Pascale
Halpern, Allan C.
Kittler, Harald
Malvehy, Josep
Liopyris, Konstantinos
Mar, Victoria J.
Martin, Linda K.
Maul, Lara Valeska
Navarini, Alexander
Rajeswaran, Tarlia
Rajeswaran, Vin
Reichman, Nadia
Soyer, H. Peter
Weber, Jochen
Yan, Siyuan
Rotemberg, Veronica
Kose, Kivanc
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748, P30 CA008748)
U.S. Department of Defense (HT94252410552, HT94252410552, HT94252410552)
- License Information
-
More Information
Article History
Received: 2 July 2025
Accepted: 7 October 2025
First Online: 21 November 2025
Competing interests
: B. D’Alessandro is an employee of Canfield Scientific, Inc. N. Codella is a Microsoft employee and holds diverse investments in the technology and healthcare sectors. P. Guitera has participated in Advisory Boards for MSD and L’Oreal and received honoraria from Metaoptima PTY and travel support from L’Oréal. Neither of these is relevant for this paper. A. Halpern receives consultation fees from Canfield Scientific, Inc. A. Navarini and L.V. Maul received a grant from Canfield Scientific, Inc. for physician's salary in a separate study that had no influence on this manuscript. H.P. Soyer is a shareholder of MoleMap NZ Limited and e-derm consult GmbH and undertakes regular teledermatological reporting for both companies. H.P. Soyer is a medical consultant for Canfield Scientific Inc. and a medical advisor for First Derm. V. Rotemberg is a consultant for Inhabit Brands, Inc. and Atria Institute, and receives in-kind support from Kaggle and AWS. The other authors do not declare any competing interests.
